About Indapta Therapeutics
Indapta Therapeutics is a private company based in Houston, Texas. It has reported $84,403,273 raised in two offerings on Form D since February 2022. Its chief executive is Mark Frohlich.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2025 | Oct 14, 2025 | $50,800,176of $51.5M target | 46 | $1.1M | Equity, Includes preferred stock issued upon conversion of outstanding notes, common shares issued in exchange for preferred stock and preferred stock issued in exchange for common stock.Rule 506(b) | Form D ↗ |
| Jan 28, 2022 | Feb 10, 2022 | $33,603,097of $67.1M target | 37 | $908K | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $84,403,273 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Indapta Therapeutics's Form D filed Oct 14, 2025.
LH
Lori Hu
Director
FP
Fabio Pucci
Director
RM
Ronald Martell
Director
MF
Mark Frohlich
Chief Executive Officer and director
Earlier filings also listed Laura Stoppel (director, last listed Feb 2022) and Guy DiPierro (executive officer, last listed Feb 2022).